Esophageal cancer secondary prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| (7 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
{{Esophageal cancer}} | {{Esophageal cancer}} | ||
{{CMG}};{{AE}} {{HM}} | {{CMG}}; {{AE}} {{HM}} | ||
==Overview== | ==Overview== | ||
Secondary prevention may be effective in reducing the incidence of esophageal cancer, if treated early at the dysplasia stage with monoclonal antibody therapy. At present, there is no particular program in place to reduce the incidence of esophageal cancer. | Secondary prevention may be effective in reducing the [[incidence]] of esophageal cancer, if treated early at the [[dysplasia]] stage with [[Monoclonal antibodies|monoclonal antibody]] therapy. At present, there is no particular program in place to reduce the incidence of esophageal cancer. | ||
==Secondary Prevention== | ==Secondary Prevention== | ||
Secondary prevention can be effective in high risk groups with advanced [[dysplasia]] if they are treated (with monoclonal antibodies) early enough in the dysplastic phase before cancer occurs.<ref name="pmid3219974">{{cite journal |vauthors=Lin PZ, Zhang JS, Cao SG, Rong ZP, Gao RQ, Han R, Shu SP |title=[Secondary prevention of esophageal cancer--intervention on precancerous lesions of the esophagus] |language=Chinese |journal=Zhonghua Zhong Liu Za Zhi |volume=10 |issue=3 |pages=161–6 |year=1988 |pmid=3219974 |doi= |url=}}</ref> | |||
*A | *A high risk group who frequently smoke and drink alcohol were identified in Hishun village, China. | ||
* | *They were examined by esophageal exfoliative cytology. | ||
*One third of the participants were found to have advanced esophageal [[dysplasia]]. | |||
*One | *They were placed on an antitumor B regimen for 3 years. | ||
*Patients who were treated with monoclonal antibodies subsequently showed a reduction in the incidence of esophageal cancer by 53%. | |||
*These results demonstrate the effectiveness of secondary prevention in the prevention of esophageal cancer. | |||
*They were placed on | |||
* | |||
*These results | |||
==References== | ==References== | ||
Latest revision as of 16:48, 5 January 2018
|
Esophageal cancer Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Esophageal cancer secondary prevention On the Web |
|
American Roentgen Ray Society Images of Esophageal cancer secondary prevention |
|
Risk calculators and risk factors for Esophageal cancer secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Hadeel Maksoud M.D.[2]
Overview
Secondary prevention may be effective in reducing the incidence of esophageal cancer, if treated early at the dysplasia stage with monoclonal antibody therapy. At present, there is no particular program in place to reduce the incidence of esophageal cancer.
Secondary Prevention
Secondary prevention can be effective in high risk groups with advanced dysplasia if they are treated (with monoclonal antibodies) early enough in the dysplastic phase before cancer occurs.[1]
- A high risk group who frequently smoke and drink alcohol were identified in Hishun village, China.
- They were examined by esophageal exfoliative cytology.
- One third of the participants were found to have advanced esophageal dysplasia.
- They were placed on an antitumor B regimen for 3 years.
- Patients who were treated with monoclonal antibodies subsequently showed a reduction in the incidence of esophageal cancer by 53%.
- These results demonstrate the effectiveness of secondary prevention in the prevention of esophageal cancer.